ArticleThe Journal of clinical investigation2020

Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.

Xinxia Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.